- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Seroquel, Seroquel XR
Synonyms :
quetiapine
Class :
Atypical antipsychotics
Dosage Forms & Strengths
tablet, extended release
400mg
300mg
200mg
150mg
50mg
tablet, immediate release
400mg
300mg
200mg
100mg
50mg
25mg
Immediate release
On day 1: 50 mg daily orally divided 2 times a day
On days 2 and 3: Dosage increased every day in the increments of 25-50 mg 2-3 times a day to 300-400 mg on day 4; additional modifications may be made in the increments of 25-50 mg 2 times a day at more than 2-day intervals.
Dosage: 150-750 mg daily
Extended release
On day 1: 300 mg daily orally; subsequently, the dose can be increased by up to 300 mg/day at more than one-day intervals.
400-800 mg daily for maintenance (monotherapy).
Patients who have been discontinued treatment for more than one week should reduce their dose upon start of therapy; patients who have been discontinued treatment for less than one week may restart at their past maintenance dose.
(Depressive Episodes)
The dosage can be titrated upward over four days using either extended-release or immediate-release tablets.
Day 1: 50 mg orally before bed.
Day 2: 100 mg orally before bed.
Day 3: 200 mg orally before bed.
Maintenance (from day 4): 300 mg orally before bed
Dose Adjustments
Mania, Bipolar I Disorder
Given either monotherapy or in the combination with lithium or divalproex.
Immediately release
on day 1: 100 mg orally divided every 12 hours
on day 2: 200 mg orally divided every 12 hours.
on day 3: 300 mg daily orally divided every 12 hours
on day 4: 400 mg daily orally divided every 12 hours
Additional dosage modifications, up to 800 mg daily by day 6, should be given in 200 mg/day increments.
Dosage: 400-800 mg daily, should not exceed more than 800 mg daily
.
Extended release
On Day 1: 300 mg orally once a day
On Day 2: 600 mg orally once a day
Maintenance (after day 3): 400-800 mg daily orally
Maintenance, Bipolar I Disorder
Given in addition to divalproex or lithium
400-800 mg daily orally divided every 12 hours for immediate release
400-800 mg daily orally in a single dose, extended release
In general, patients in the maintenance phase continue to receive the same dose that was used to stabilise them.
Antidepressant extended-release formulation
On days 1 & 2: 50 mg orally in the evening
Day 3: The dose can be increased to 150 mg orally in the evening.
Dosage range: 150-300 mg/day
Insomnia (Off-label)
Initially, 25 mg orally daily at bedtime.
Alcohol Dependence (Off-label)
25-50 mg orally at bedtime; can be titrated; should not exceed more than 300 mg
Dosage Forms & Strengths
tablet, extended release
400mg
300mg
200mg
150mg
50mg
tablet, immediate release
400mg
300mg
200mg
100mg
50mg
25mg
Below 12 years
Safety and efficacy were not established
Above 12 years (immediate release, monotherapy,)
Day 1: 50 mg daily orally divided 2 times a day
Day 2: 100 mg daily orally divided 2 times a day
Day 3: 200 mg daily orally divided 2 times a day
Day 4: 300 mg daily orally divided 2 times a day
Day 5: 400 mg daily orally divided 2 times a day; further dose modifications should be less than 100 mg daily in increments
Dosage: 400-800 mg daily
Depending on tolerance and response, the daily dose can be divided 3 times a day
Above 12 yrs (extended release, monotherapy)
Day 1: 50 mg orally once a day
Day 2: 100 mg orally once a day
Day 3: 200 mg orally once a day
Day 4: 300 mg orally once a day
Day 5: 400 mg orally once a day; further dose modifications should be less than 100 mg daily in increments
Mania, Bipolar I Disorder
Below 10 yrs
Safety and efficacy were not established
Above 10 years (immediate release,monotherapy)
Day 1: 50 mg daily orally divided 2 times a day
Day 2: 100 mg daily orally divided 2 times a day
Day 3: 200 mg daily orally divided 2 times a day
Day 4: 300 mg daily orally divided 2 times a day
Day 5: 400 mg daily orally divided 2 times a day; further dose modifications should be less than 100 mg daily in increments
Dosage: 400-600 mg daily
Depending on tolerance and response, the daily dose can be divided 3 times a day
Above 10 years (extended release, monotherapy)
Day 1: 50 mg orally once a day
Day 2: 100 mg orally once a day
Day 3: 200 mg orally once a day
Day 4: 300 mg orally once a day
Day 5: 400 mg orally once a day; further dose modifications should be less than 100 mg daily in increments
Dosage: 400-600 mg daily once
Dosage Forms & Strengths
Because of the increased risk of infectious or the cardiovascular related deaths, this medication is not approved for the dementia-related psychosis.
50-200 mg/day orally for immediate release; can increase to 25-50 mg daily
50 mg/day orally for extended release; may can be increased to 50 mg daily.
Dose Adjustments
Alzheimer's Disease-Related Psychosis and Agitation (Off-label)
12.5-50 mg daily orally at start; increased gradually as tolerated; should not exceed more than 200-300 mg daily
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
quetiapine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
quetiapine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
quetiapine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
quetiapine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
quetiapine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
QTc interval is increased both by lenvatinib and quetiapin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of quetiapine
it decreases the effects of antipsychotic agents
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may increase the adverse effect of amphetamines
may increase the adverse effect of amphetamines
may increase the adverse effect of amphetamines
may increase the adverse effect of amphetamines
may increase the adverse effect of amphetamines
It may enhance sedation when combined with a shepherd's purse
It may enhance the metabolism when combined with dexamethasone
quetiapine: they may diminish the serum concentration of CYP3A4 Inducers
quetiapine: they may diminish the serum concentration of CYP3A4 Inducers
quetiapine: they may diminish the serum concentration of CYP3A4 Inducers
quetiapine: they may diminish the serum concentration of CYP3A4 Inducers
quetiapine: they may diminish the serum concentration of CYP3A4 Inducers
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
the effect of quetiapine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
serotonergic Agents may enhance the adverse/toxic effect of antipsychotic Agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may increase the hypotensive effect of anti-hypertensives
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may increase the hypotensive effect of blood pressure-lowering agents
may enhance the bradycardic effect of beta blockers
may increase the hypotensive effect of blood pressure-lowering agents
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may have an increasingly adverse effect when combined with antipsychotic agent
